[{"address1": "885 West Georgia Street", "address2": "Suite 1445", "city": "Vancouver", "state": "BC", "zip": "V6C 3E8", "country": "Canada", "phone": "604 669 7207", "fax": "778 945 6800", "website": "https://www.inmedpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.", "fullTimeEmployees": 13, "companyOfficers": [{"maxAge": 1, "name": "Mr. Eric A. Adams B.S. Chem., M.I.B.", "age": 62, "title": "President, CEO & Director", "yearBorn": 1963, "fiscalYear": 2025, "totalPay": 377129, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. N. Netta Jagpal", "age": 52, "title": "CFO & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2025, "totalPay": 291813, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Woudenberg P.Eng.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1969, "fiscalYear": 2025, "totalPay": 335216, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric Chih-Hsien Hsu Ph.D.", "age": 55, "title": "Senior Vice President of Preclinical Research & Development", "yearBorn": 1970, "fiscalYear": 2025, "totalPay": 314891, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sazzad  Hossain M.Sc., Ph.D.", "age": 67, "title": "Co-Founder", "yearBorn": 1958, "fiscalYear": 2025, "totalPay": 134629, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Colin  Clancy", "title": "Senior Director of Investor Relations", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jerry P. Griffin", "title": "Vice President of Sales & Marketing", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shane A. Johnson Ph.D.", "title": "Senior VP & GM of BayMedica", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.06, "open": 1.06, "dayLow": 1.055, "dayHigh": 1.1363, "regularMarketPreviousClose": 1.06, "regularMarketOpen": 1.06, "regularMarketDayLow": 1.055, "regularMarketDayHigh": 1.1363, "payoutRatio": 0.0, "beta": 0.314, "forwardPE": -0.1792, "volume": 44952, "regularMarketVolume": 44952, "averageVolume": 369760, "averageVolume10days": 144450, "averageDailyVolume10Day": 144450, "bid": 0.9144, "ask": 1.54, "bidSize": 2, "askSize": 2, "marketCap": 3140688, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 8.27, "allTimeHigh": 32175.0, "allTimeLow": 1.03, "priceToSalesTrailing12Months": 0.65456694, "fiftyDayAverage": 1.5043, "twoHundredDayAverage": 2.29293, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -4304598, "profitMargins": -1.7113299, "floatShares": 2799465, "sharesOutstanding": 2804186, "sharesShort": 166145, "sharesShortPriorMonth": 30173, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0592, "heldPercentInsiders": 0.00147, "heldPercentInstitutions": 0.13692, "shortRatio": 0.18, "shortPercentOfFloat": 0.059699997, "impliedSharesOutstanding": 2804186, "bookValue": 2.931, "priceToBook": 0.38212216, "lastFiscalYearEnd": 1751241600, "nextFiscalYearEnd": 1782777600, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -8211164, "trailingEps": -6.09, "forwardEps": -6.25, "lastSplitFactor": "1:20", "lastSplitDate": 1731542400, "enterpriseToRevenue": -0.897, "enterpriseToEbitda": 0.558, "52WeekChange": -0.78672034, "SandP52WeekChange": 0.14561749, "quoteType": "EQUITY", "currentPrice": 1.12, "recommendationKey": "none", "totalCash": 9373936, "totalCashPerShare": 2.37, "ebitda": -7715931, "totalDebt": 640243, "quickRatio": 6.249, "currentRatio": 6.945, "totalRevenue": 4798116, "debtToEquity": 5.524, "revenuePerShare": 1.213, "returnOnAssets": -0.4159, "returnOnEquity": -0.82168996, "grossProfits": 1616332, "freeCashflow": -3951429, "operatingCashflow": -7547757, "revenueGrowth": -0.114, "grossMargins": 0.33687, "ebitdaMargins": -1.60812, "operatingMargins": -1.5745399, "financialCurrency": "USD", "symbol": "INM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 5.66038, "regularMarketPrice": 1.12, "shortName": "InMed Pharmaceuticals Inc.", "longName": "InMed Pharmaceuticals Inc.", "corporateActions": [], "postMarketTime": 1767395674, "regularMarketTime": 1767387601, "exchange": "NCM", "messageBoardId": "finmb_9199217", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChange": -0.3843, "fiftyDayAverageChangePercent": -0.25546765, "twoHundredDayAverageChange": -1.1729299, "twoHundredDayAverageChangePercent": -0.51154196, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1399296600000, "postMarketChangePercent": -0.8928563, "postMarketPrice": 1.11, "postMarketChange": -0.00999999, "regularMarketChange": 0.0600001, "regularMarketDayRange": "1.055 - 1.1363", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 369760, "fiftyTwoWeekLowChange": 0.09000003, "fiftyTwoWeekLowChangePercent": 0.08737867, "fiftyTwoWeekRange": "1.03 - 8.27", "fiftyTwoWeekHighChange": -7.1500006, "fiftyTwoWeekHighChangePercent": -0.86457074, "fiftyTwoWeekChangePercent": -78.672035, "dividendDate": 1593993600, "earningsTimestampStart": 1763040600, "earningsTimestampEnd": 1763040600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -6.09, "epsForward": -6.25, "marketState": "CLOSED", "displayName": "InMed Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-01-03"}]